The Pharmaceutical Digital Platform Market was valued at USD 4.92 billion in 2023. The industry is projected to grow from USD 5.97 billion in 2024 to USD 34.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 24.35% during the forecast period (2024 - 2032). The increasing adoption of digital health solutions and growing penetration of the internet, coupled with the growing digitization in healthcare infrastructure are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Pharmaceutical Digital Platform Market Trends
Increasing Adoption of Digital Health Solutions
Digital health encompasses a wide range of categories, including mobile health (mHealth), health information technology (IT), wearable devices, telehealth and telemedicine, as well as personalized medicine. From mobile medical applications and decision-support software for doctors to advanced technologies like artificial intelligence and machine learning, these digital innovations have transformed healthcare. Digital medical tools offer immense potential to enhance the accuracy of diagnoses, improve treatment approaches, and elevate healthcare delivery for the population. Utilizing computing platforms, connectivity, software, and sensors, digital health technologies assist individuals in maintaining their health. These technologies empower patients and consumers to manage and monitor their health and wellness more effectively. With the rise of smartphones, social networks, and internet applications, communication methods are evolving, while also providing innovative ways to track health and well-being and expand access to information. These advancements are integrating people, information, technology, and connectivity to enhance healthcare and health outcomes.
For instance, according to survey conducted by American Medical Association (AMA), the use of digital tools has increased substantially among physicians across all demographics, including gender, specialty, and age. The average number of digital health tools utilized by a physician rose from 2.2 in 2016 to 3.8 in 2022. The proportion of physicians conducting tele-visits or virtual visits increased significantly, from 14% in 2016 to 80% in 2022. Similarly, the percentage of physicians utilizing remote monitoring devices rose from 12% in 2016 to 30% in 2022
Pharmaceutical Digital Platform Market Segment Insights:
Global Pharmaceutical Digital Platform Services Insight
Based on Services, the Pharmaceutical Digital Platform Market has been segmented into Tele Consultation, In-Person Care, Vaccine Scheduling, and Medicine Delivery. The Tele Consultation segment dominated the market in 2023, and Medicine Delivery is projected to be the fastest-growing segment during the forecast period, 2024–2032.
For Instance, as of February 2023, more than 7.4 million teleconsultations had been conducted through the eSanjeevani portal in India, reflecting a steady rise since March 2022. These consultations took place at various Ayushman Bharat Health and Wellness Centers across the country. The eSanjeevani platform was launched by the Union Ministry of Health and Family Welfare as a national telemedicine service. eSanjeevani facilitates remote medical consultations, making healthcare more accessible, especially for individuals in rural and underserved areas. The platform operates through various Ayushman Bharat Health and Wellness Centers, providing a range of services from primary care to specialized consultations.
FIGURE 2: PHARMACEUTICAL DIGITAL PLATFORM MARKET SIZE, BY SERVICES, 2023 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Global Pharmaceutical Digital Platform Disease Insight
Based on Disease, the Pharmaceutical Digital Platform Market has been segmented into Migraine, Diabetes, Obesity, Pneumococcal pneumonia, Flu, and Others. The Diabetes segment dominated the market in 2023, and obesity is projected to be the fastest-growing segment during the forecast period, 2024–2032.
For Instance, according to IDF Diabetes Atlas, in 2021, approximately 537 million adults aged 20 to 79 were living with diabetes, equating to 1 in 10 individuals. This figure is expected to rise to 643 million by 2030 and 783 million by 2045. Notably, more than three-quarters of adults with diabetes reside in low- and middle-income countries. The disease was responsible for 6.7 million deaths in 2021, translating to one death every five seconds. Additionally, diabetes incurred health expenditures of at least USD 966 billion, marking a staggering 316% increase over the past 15 years.
Additionally, in 2022, 1 in 8 people globally were living with obesity. Since 1990, adult obesity has more than doubled, while adolescent obesity has quadrupled. That year, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight and 16% were obese. Additionally, 37 million children under the age of 5 were identified as overweight, and over 390 million children and adolescents aged 5 to 19 were also overweight, including 160 million who were living with obesity
Global Pharmaceutical Digital Platform End Use Insight
Based on end use, the Pharmaceutical Digital Platform Market has been segmented into Disease Treatment, and Disease Prevention. The Disease Treatment segment dominated the market in 2023, and Disease Prevention is projected to be the fastest-growing segment during the forecast period, 2024–2032.
Disease treatment involves a comprehensive approach to managing and alleviating the effects of illnesses, focusing on restoring health and enhancing the quality of life for patients. Disease treatment and disease prevention are closely interconnected, as effective treatment strategies can significantly impact prevention efforts. When diseases are treated promptly and appropriately, it can reduce the overall prevalence and severity of the disease in the population.
In contrast, Disease Prevention is proactive, aiming to avert the onset of diseases before they occur. This can be achieved through primary prevention measures like vaccinations, health education, and lifestyle modifications that reduce risk factors. Secondary prevention involves early detection and prompt intervention to halt disease progression, while tertiary prevention focuses on managing existing conditions to prevent further deterioration
Global Pharmaceutical Digital Platform Regional Insights
Based on region, the Pharmaceutical Digital Platform Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023.
North America accounted for the largest market share and is estimated to dominate the Pharmaceutical Digital Platform Market. In 2021, crude estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, were living with diabetes. Additionally, heart disease remains the leading cause of death across men, women, and various racial and ethnic groups in the United States. On average, someone dies from cardiovascular disease every 33 seconds. In 2022, heart disease claimed the lives of 702,880 individuals, accounting for approximately 1 in every 5 deaths.
The Americas region is followed by Europe, which accounted for the second largest Pharmaceutical Digital Platform market share. In 2020, Germany led the EU Member States in current healthcare expenditure, amounting to €432 billion. France followed with €281 billion, while Italy and Spain recorded €160 billion and €120 billion, respectively. Current healthcare spending in Germany and France represented 12.8% and 12.2% of their gross domestic product (GDP), the highest percentages among EU countries. Austria (11.5%), Sweden (11.4%), the Netherlands (11.1%), and Belgium (11.1%) had the next highest ratios. Spain, Portugal, and Denmark were the only other EU Member States with double-digit ratios. Additionally, Switzerland had a current healthcare expenditure of 11.8% of GDP, and Norway also reported a double-digit ratio based on 2019 data. In contrast, six Member States spent less than 7.5% of GDP on healthcare, with Luxembourg having the lowest ratio.
FIGURE 3: PHARMACEUTICAL DIGITAL PLATFORM MARKET BY REGION 2023 & 2032 (USD BILLION)
Global Pharmaceutical Digital Platform Key Market Players & Competitive Insights
The Pharmaceutical Digital Platform Market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive, with all the players competing to gain maximum market share. Intense competition, frequent changes in government policies, and regulations are key factors that impact market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services.
Product launch and approvals were also observed to expand the company's product portfolio. The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that increasing investment in healthcare infrastructure and rising awareness and education associated with the Pharmaceutical Digital Platform benefits will also boost the market's growth in the upcoming future.
Major players in the Pharmaceutical Digital Platform Market, including AstraZeneca, Pfizer, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and others are making investments in R&D activities to boost market demand.
In January 2024, Eli Lilly and Company has introduced LillyDirect, a new digital healthcare platform designed for patients in the U.S. managing obesity, migraine, and diabetes. This service provides disease management resources, access to independent healthcare providers, personalized support, and direct home delivery of select Lilly medications via third-party pharmacy services.
Moreover, In August 2024, Pfizer Inc. has launched PfizerForAll, a user-friendly digital platform aimed at simplifying healthcare access and health management for individuals across the U.S. This comprehensive service is designed to assist the millions affected each year by common illnesses such as migraine, COVID-19, and the flu, as well as those looking for adult vaccinations. By consolidating essential resources and services in one place, PfizerForAll enables individuals and their families to streamline important health actions like seeking care, filling prescriptions, and discovering potential savings on Pfizer medications.
Key Companies in the Pharmaceutical Digital Platform Market include.
Global Pharmaceutical Digital Platform Industry Developments
August 2024: Pfizer Inc. has launched Pfizer ForAll, a user-friendly digital platform aimed at simplifying healthcare access and health management for individuals across the U.S. This comprehensive service is designed to assist the millions affected each year by common illnesses such as migraine, COVID-19, and the flu, as well as those looking for adult vaccinations.
January 2024: Eli Lilly and Company has introduced LillyDirect, a new digital healthcare platform designed for patients in the U.S. managing obesity, migraine, and diabetes. This service provides disease management resources, access to independent healthcare providers, personalized support, and direct home delivery of select Lilly medications via third-party pharmacy services.
November 2023: AstraZeneca has introduced Evinova, aiming to be a key player in digital health solutions tailored for healthcare professionals, regulators, and patients. Backed by AstraZeneca and in collaboration with Parexel and Fortrea, Evinova is set to deliver scalable digital products and services for the life sciences and healthcare sectors. This initiative highlights a commitment to enhancing healthcare delivery and improving patient outcomes through innovative technology.
Pharmaceutical Digital Platform Market Segmentation:
Global Pharmaceutical Digital Platform Services Outlook
Global Pharmaceutical Digital Platform Disease Outlook
Global Pharmaceutical Digital Platform End Use Outlook
Global Pharmaceutical Digital Platform Regional Outlook
North America
Europe
Asia-Pacific
Rest of the World
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 4.92 billion |
| Market Size 2024 | USD 5.97 billion |
| Market Size 2032 | USD 34.12 billion |
| Compound Annual Growth Rate (CAGR) | 24.35% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends. |
| Segments Covered | Services, Disease, End Use, and Region. |
| Key Companies Profiled | AstraZeneca (UK), Pfizer, Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Sanofi (France), Astellas Pharma Inc. (Japan), Boehringer Ingelheim International GmbH (Germany), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US). |
| Key Market Opportunities | · Rising awareness and education associated with the pharmaceutical digital platform |
| Key Market Dynamics | · Increasing adoption of digital health solution · Growing penetration of the internet, coupled with the growing digitization in healthcare infrastructure. |
Frequently Asked Questions (FAQ) :
The Pharmaceutical Digital Platform Market is anticipated to reach 34.12 billion at a CAGR of 24.35% during the forecast period of 2024-2032.
The Pharmaceutical Digital Platform Market is expected to grow at a 24.35% CAGR during the forecast period from 2024 to 2032.
The North America region market is estimated to hold the largest market share in the Pharmaceutical Digital Platform Market.
The key players include AstraZeneca (UK), Pfizer, Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Sanofi (France), Astellas Pharma Inc. (Japan), Boehringer Ingelheim International GmbH (Germany), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US).
Tele Consultation segment dominated the market in 2023.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
